Seronegative antiphospholipid syndrome

Rheumatology (United Kingdom)

Volumn 52, Issue 8, 2013, Pages 1358-1367

  Nayfe, Rabih ^a   Uthman, Imad ^a   Aoun, Jessica ^a   Aldin, Ehab Saad ^a,b   Merashli, Mira ^a   Khamashta, Munther A ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti 2 glycoprotein I antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Phosphatidylethanolamine; Pregnancy morbidity; Seronegative antiphospholipid syndrome; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5A; CARDIOLIPIN; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; IMMUNOGLOBULIN A; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHATIDIC ACID; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PREKALLIKREIN; PROTHROMBIN; VIMENTIN;

ANTICOAGULATION; ANTIGENICITY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BIOSYNTHESIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; CHEMOLUMINESCENCE; CROSS REACTION; DIAGNOSTIC VALUE; FETUS RESORPTION; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; INTERMEDIATE FILAMENT; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PATHOGENICITY; PERINATAL DEATH; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; VEIN THROMBOSIS; WESTERN BLOTTING;

ANTI-Β2 GLYCOPROTEIN I ANTIBODIES; ANTIPHOSPHOLIPID ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; PHOSPHATIDYLETHANOLAMINE; PREGNANCY MORBIDITY; SERONEGATIVE ANTIPHOSPHOLIPID SYNDROME; THROMBOSIS;

ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHOSPHATIDYLETHANOLAMINES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROGNOSIS; RISK ASSESSMENT; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84880581144     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket126     Document Type: Review

References (105)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Kaul M, Erkan D, Sammaritano L et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007;66:927-30.
3. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003;62:1127.
4. Lazurova I, Macejova Z, Tomkova Z et al. Severe limb necrosis: primary thrombotic microangiopathy or 'seronegative' catastrophic antiphospholipid syndrome? A diagnostic dilemma. Clin Rheumatol 2007; 26:1737-40.
5. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called 'seronegative antiphospholipid syndrome'. Autoimmun Rev 2009;9: 90-2.
6. Giannakopoulos B, Passam F, Ioannou Y et al. How we diagnose the antiphospholipid syndrome. Blood 2009; 113:985-94.
7. Cervera R, Boffa MC, Khamashta MA et al. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009;18:889-93.
8. McIntyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000;185-93.
9. Smirnov MD, Ford DA, Esmon CT et al. The effect of membrane composition on the hemostatic balance. Biochemistry 1999;38:3591-8.
10. Tsuda T, Yoshimura H, Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis 2006;17:465-9
11. Baumgártner P, Geiger M, Zieseniss S et al. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J Cell Biol 2007; 179:793-804.
12. Rauch J, Tannenbaum M, Neville C et al. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998;80:936-41.
13. Sugi T, Mclntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996;76:936-41.
14. Sugi T, McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001;17:207-14.
15. Berard M, Chantome R, Marcelli A et al. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996;23:1369-74.
16. Sugi T, Katsunuma J, Izumi S et al. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999;71:1060-5.
17. Gris JC, Quere I, Sanmarco M et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study-NOHA. Thromb Haemost 2000; 84:y.
18. Sanmarco M, Alessi MC, Harle JR et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001;85:800-5.
19. Sugi T, Matsubayashi H, Inomo A et al. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004;30:326-32.
20. Sanmarco M, Gayet S, Alessi MC et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007;97: 949-54.
21. Hirmerova J, Ulcova-Gallova Z, Seidlerova J et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010;16:318-25.
22. Tian Y, Jackson P, Gunter C et al. Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2. J Biol Chem 2006;281:28438-49.
23. Velayuthaprabhu S, Matsubayashi H, Sugi T et al. A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol 2011;66:373-84.
24. Sanmarco M. Is testing for antiphosphatidylethanolamine antibodies clinically useful? Curr Rheumatol Rep 2011;13: 81-5.
25. Staub HL, Harris EN, Khamashta MA et al. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989;48: 166-9.
26. Hirmerova J, Ulcova-Gallova Z, Seidlerova J et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010;16:318-25.
27. Bertolaccini ML, Amengual O, Atsumi T et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011;20:191-205.
28. Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012;12:230-4.
29. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996;66:540-6.
30. Kutteh WH, Corey A, Jaslow CR. Antiphospholipid antibodies and recurrent pregnancy loss: prevalence of anticardiolipin antibodies, the lupus anticoagulant, and antiphosphatidyl serine antibodies. Lupus 2010;19:C156. (abstract).
31. Katsuragawa H, Kanzaki H, Inoue T et al. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod 1997;56:50-8.
32. Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003;101:455-62.
33. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002;17:2981-5.
34. Gharavi AE, Harris EN, Asherson RA et al. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
35. Campbell AL, Pierangeli SS, Wellhausen S et al. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995;73:529-34.
36. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus 1998; 7(Suppl 2):S52-4.
37. Laroche P, Berard M, Rouquette AM et al. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 1996;106:549-54.
38. Branch DW, Silver R, Pierangeli S et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;89:549-55.
39. Amoroso A, Mitterhofer AP, Del Porto F et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003;64:265-73.
40. Tebo AE, Jaskowski TD, Phansalkar AR et al. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol 2008;129:870-5.
41. Tebo AE, Jaskowski TD, Hill HR et al. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol 2008;154:332-8.
42. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10: 457-60.
43. de Laat B, Derksen RH, van Lummel M et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006;107:1916-24.
44. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998;95:15542-6.
45. Iverson GM, Reddel S, Victoria EJ et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002;169:7097-103.
46. Ioannou Y, Pericleous C, Giles I et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56: 280-90.
47. Caronti B, Calderaro C, Alessandri C et al. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol 1999; 115:214-9.
48. Conti F, Sorice M, Circella A et al. Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003;132: 509-16.
49. Lin WS, Chen PC, Yang CD et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007; 56:1638-47.
50. Ramesh S, Morrell CN, Tarango C et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest 2011;121:120-31.
51. de Laat B, Derksen RH, Urbanus RT et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105: 1540-5.
52. de Laat B, Pengo V, Pabinger I et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767-73.
53. Ioannou Y, Romay-Penabad Z, Pericleous C et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
54. Mahler M, Norman GL, Meroni PL et al. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012;12:313-7.
55. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006;79: 489-98.
56. Boilard E, Bourgoin SG, Bernatchez C et al. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 2003;102:2901-9.
57. Mor-Vaknin N, Punturieri A, Sitwala K et al. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003;5: 59-63.
58. Podor TJ, Singh D, Chindemi P et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002;277:7529-39.
59. Xu B, deWaal RM, Mor-Vaknin N et al. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol 2004;24: 9198-206.
60. Ortona E, Capozzi A, Colasanti T et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010;116:2960-7.
61. Sorice M, Circella A, Misasi R et al. Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin Exp Immunol 2000;122: 277-84.
62. Sorice M, Circella A, Cristea IM et al. Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ 2004;11:1133-45.
63. Alessandri C, Conti F, Pendolino M et al. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011;10:609-16.
64. Pengo V, Biasiolo A, Brocco T et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-4.
65. Bertolaccini ML, Atsumi T, Khamashta MA et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998;25:1104-8.
66. Vaarala O, Puurunen M, Manttari M et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996;75:456-9.
67. Horbach DA, van Oort E, Donders RC et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
68. Galli M, Beretta G, Daldossi M et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486-91.
69. Forastiero RR, Martinuzzo ME, Cerrato GS et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008-14.
70. Donohoe S, MacKie IJ, Isenberg D et al. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001;113: 544-9.
71. Tincani A, Morozzi G, Afeltra A et al. Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 2007;25:268-74.
72. Palosuo T, Virtamo J, Haukka J et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb Haemost 1997;78: 1178-82.
73. Tsutsumi A, Hayashi T, Chino Y et al. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol 2006;16:158-64.
74. Atsumi T, Ieko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43: 1982-93.
75. Forastiero R, Martinuzzo M, Pombo G et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005;3:1231-8.
76. Bizzaro N, Ghirardello A, Zampieri S et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-64.
77. Forastiero R, Martinuzzo M, Iglesias Varela ML et al. Multiple (triple or quadruple) aPL positivity is much more prevalent in patients with definite antiphospholipid syndrome. Lupus 2010;19:109-110.
78. Bertolaccini ML, Atsumi T, Koike T et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005;93:289-97.
79. Atsumi T, Koike T. Antiprothrombin antibody: why do we need more assays? Lupus 2010;19:436-9.
80. Frank M, Sodin-Semrl S, Irman S et al. Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. Autoimmun Rev 2009;9:5-10.
81. Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996;5:388-92.
82. Rand JH, Wu XX, Quinn AS et al. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008;17:922-30.
83. Rand JH, Wu XX, Lapinski R et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004;104:2783-90.
84. de Laat B, Wu XX, van Lummel M et al. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007;109: 1490-4.
85. Rand JH, Arslan AA, Wu XX et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006;194: 182-8.
86. Nojima J, Kuratsune H, Suehisa E et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47: 1008-15.
87. Arnold J, Holmes Z, Pickering W et al. Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage. Br J Haematol 2001;113: 911-4.
88. de Laat B, Derksen RH, Mackie IJ et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006;65:1468-72.
89. Frostegard AG, Su J, von Landenberg P et al. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease. Scand J Rheumatol 2010;39:77-83.
90. Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F et al. IgA anticardiolipin antibodies - relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998;79:282-5.
91. Weidmann CE, Wallace DJ, Peter JB et al. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988;15:74-9.
92. Molina JF, Gutierrez-Urena S, Molina J et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997;24:291-6.
93. Wong KL, Liu HW, Ho K et al. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991;18:1187-92.
94. Pierangeli SS, Liu XW, Barker JH et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995;74:1361-7.
95. Cucurull E, Gharavi AE, Diri E et al. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55-60.
96. Lakos G, Kiss E, Regeczy N et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574-9.
97. Staub HL, Norman GL, Crowther T et al. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr 2003;61:757-63.
98. Staub HL, Franck M, Ranzolin A et al. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 2006;6:104-6.
99. Ranzolin A, Bohn JM, Norman GL et al. Anti-beta2- glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol 2004;83:141-4, 137-40.
100. Franck M, Staub HL, Petracco JB et al. Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology 2007;58:295-302.
101. Diri E, Cucurull E, Gharavi AE et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999;8:263-8.
102. Bertolaccini ML, Atsumi T, Escudero Contreras A et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28: 2637-43.
103. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010;19: 419-23.
104. Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006;33:1775-9.
105. Mehrani T, Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2011;38: 64-8.